A year after the onslaught of the global pandemic, FPI inflows, corporate
performance, and news of the vaccines were key to the Indian equity markets’
immunity against Covid-19.
The Covid-19 pandemic failed to affect the bulls’ spirits, as benchmark indices saw absolute annual gains between 75.2% and 117.2% while FPIs pumped in a record ₹2.74 lakh crore into equities.
According to a BofA Securities report, the Covid-19 shock could delay India touching the GDP of Japan by three years. In their latest estimates, it will now happen by 2031 if the economy grows at 9%.
Rising inflation and firming bond yields in the U.S. push down Indian benchmark indices, causing a correction of around 6% from the latest life–highs of February 16.
Absence of new taxes, no tweaking of older ones, infrastructure capex focus, and stronger disinvestment intent boosts equity indices, with the Sensex recording its best Budget-day gains since 1997.
Despite the Survey’s positive tone, the Sensex and Nifty 50 closed in the red, falling nearly 8% in a matter of five trading sessions from their January 21 life–high.
While the mutual fund industry assets under management crossed ₹31 lakh crore, MFs continued to reel under record–high redemption pressure in December. What would the new year bring?
While the year was marred by the Covid-19 pandemic, lockdowns, and negative GDP, the equity benchmark indices, however, saw record highs. Will the trend continue in 2021 too?
Fears over a new strain of the Coronavirus, discovered in the U.K., hit India's stock market on Monday, with benchmark equities witnessing the hardest fall in the past seven months.
